As­traZeneca's block­buster Farx­i­ga se­cures land­mark ap­proval in heart fail­ure pa­tients, re­gard­less of whether they have di­a­betes

Last Oc­to­ber, the FDA cleared the use of As­traZeneca’s block­buster ther­a­py Farx­i­ga to re­duce the risk of hos­pi­tal­iza­tion for heart fail­ure in pa­tients with type 2 di­a­betes and es­tab­lished car­dio­vas­cu­lar dis­ease or CV risk fac­tors. Now, the US agency has opened up the use of the di­a­betes drug in an even big­ger pop­u­la­tion: to re­duce the risk of CV death and hos­pi­tal­iza­tion for heart fail­ure in all pa­tients, even those that don’t have di­a­betes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER